



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SECOND QUARTER					SIX MONTHS				
	2009	2008	% Change			2009	2008	% Change		
			Reported	Operational (1)	Currency			Reported	Operational (1)	Currency
CONSUMER SEGMENT ⁽²⁾										
SKIN CARE										
US	411	379	8.4%	8.4%	-	834	761	9.6%	9.6%	-
Intl	422	460	-8.3%	3.8%	-12.1%	841	918	-8.4%	4.6%	-13.0%
WW	833	839	-0.7%	5.9%	-6.6%	1,675	1,679	-0.2%	6.9%	-7.1%
BABY CARE										
US	104	111	-6.3%	-6.3%	-	206	226	-8.8%	-8.8%	-
Intl	404	461	-12.4%	-1.2%	-11.2%	791	879	-10.0%	1.5%	-11.5%
WW	508	572	-11.2%	-2.2%	-9.0%	997	1,105	-9.8%	-0.7%	-9.1%
ORAL CARE										
US	174	185	-5.9%	-5.9%	-	362	384	-5.7%	-5.7%	-
Intl	212	223	-4.9%	9.5%	-14.4%	389	410	-5.1%	10.4%	-15.5%
WW	386	408	-5.4%	2.4%	-7.8%	751	794	-5.4%	2.6%	-8.0%
OTC/NUTRITIONALS										
US	679	679	-	-	-	1,405	1,521	-7.6%	-7.6%	-
Intl	631	726	-13.1%	0.6%	-13.7%	1,253	1,478	-15.2%	-0.9%	-14.3%
WW	1,310	1,405	-6.8%	0.3%	-7.1%	2,658	2,999	-11.4%	-4.3%	-7.1%
WOMEN'S HEALTH										
US	152	158	-3.8%	-3.8%	-	301	306	-1.6%	-1.6%	-
Intl	329	346	-4.9%	8.8%	-13.7%	603	659	-8.5%	4.9%	-13.4%
WW	481	504	-4.6%	4.8%	-9.4%	904	965	-6.3%	2.8%	-9.1%
WOUND CARE / OTHER										
US	188	182	3.3%	3.3%	-	326	315	3.5%	3.5%	-
Intl	148	126	17.5%	33.6%	-16.1%	254	243	4.5%	19.4%	-14.9%
WW	336	308	9.1%	15.7%	-6.6%	580	558	3.9%	10.4%	-6.5%
TOTAL CONSUMER										
US	1,708	1,694	0.8%	0.8%	-	3,434	3,513	-2.2%	-2.2%	-
Intl	2,146	2,342	-8.4%	4.7%	-13.1%	4,131	4,587	-9.9%	3.6%	-13.5%
WW	3,854	4,036	-4.5%	3.1%	-7.6%	7,565	8,100	-6.6%	1.0%	-7.6%

* See footnotes on page 3



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SECOND QUARTER					SIX MONTHS				
	2009	2008	% Change			2009	2008	% Change		
			Reported	Operational (1)	Currency			Reported	Operational (1)	Currency
PHARMACEUTICAL SEGMENT ⁽²⁾										
ACIPHEX/PARIET										
US	128	153	-16.3%	-16.3%	-	266	269	-1.1%	-1.1%	-
Intl	132	172	-23.3%	-10.6%	-12.7%	257	333	-22.8%	-9.5%	-13.3%
WW	260	325	-20.0%	-13.3%	-6.7%	523	602	-13.1%	-5.7%	-7.4%
CONCERTA										
US	233	208	12.0%	12.0%	-	502	432	16.2%	16.2%	-
Intl	84	71	18.3%	38.0%	-19.7%	159	137	16.1%	37.6%	-21.5%
WW	317	279	13.6%	18.7%	-5.1%	661	569	16.2%	21.4%	-5.2%
DURAGESIC/FENTANYL TRANSDERMAL										
US	50	70	-28.6%	-28.6%	-	125	145	-13.8%	-13.8%	-
Intl	168	202	-16.8%	-6.5%	-10.3%	324	360	-10.0%	1.8%	-11.8%
WW	218	272	-19.9%	-12.3%	-7.6%	449	505	-11.1%	-2.7%	-8.4%
LEVAQUIN/FLOXIN										
US	343	330	3.9%	3.9%	-	751	804	-6.6%	-6.6%	-
Intl	19	21	-9.5%	7.3%	-16.8%	36	43	-16.3%	2.0%	-18.3%
WW	362	351	3.1%	4.1%	-1.0%	787	847	-7.1%	-6.2%	-0.9%
PROCRIT/EPREX										
US	330	346	-4.6%	-4.6%	-	651	680	-4.3%	-4.3%	-
Intl	247	306	-19.3%	-7.6%	-11.7%	476	601	-20.8%	-8.7%	-12.1%
WW	577	652	-11.5%	-6.0%	-5.5%	1,127	1,281	-12.0%	-6.3%	-5.7%
RAZADYNE/REMINYL										
US	16	42	-61.9%	-61.9%	-	29	92	-68.5%	-68.5%	-
Intl	91	110	-17.3%	-4.2%	-13.1%	179	209	-14.4%	0.2%	-14.6%
WW	107	152	-29.6%	-20.1%	-9.5%	208	301	-30.9%	-20.8%	-10.1%
REMICADE										
US	771	684	12.7%	12.7%	-	1,508	1,360	10.9%	10.9%	-
US Exports ⁽⁴⁾	327	200	63.5%	63.5%	-	613	520	17.9%	17.9%	-
Intl	4	2	100.0%	96.2%	3.8%	9	4	125.0%	118.1%	6.9%
WW	1,102	886	24.4%	24.4%	-	2,130	1,884	13.1%	13.1%	-
RISPERDAL/RISPERIDONE										
US	70	492	-85.8%	-85.8%	-	188	1,074	-82.5%	-82.5%	-
Intl	169	220	-23.2%	-17.9%	-5.3%	326	447	-27.1%	-21.3%	-5.8%
WW	239	712	-66.4%	-64.8%	-1.6%	514	1,521	-66.2%	-64.5%	-1.7%
RISPERDAL CONSTA										
US	131	120	9.2%	9.2%	-	257	221	16.3%	16.3%	-
Intl	217	223	-2.7%	13.7%	-16.4%	416	431	-3.5%	13.8%	-17.3%
WW	348	343	1.5%	12.1%	-10.6%	673	652	3.2%	14.6%	-11.4%
TOPAMAX										
US	75	548	-86.3%	-86.3%	-	570	1,068	-46.6%	-46.6%	-
Intl	107	129	-17.1%	-2.9%	-14.2%	214	255	-16.1%	-1.4%	-14.7%
WW	182	677	-73.1%	-70.4%	-2.7%	784	1,323	-40.7%	-37.9%	-2.8%
VELCADE										
US	-	1	-100.0%	-100.0%	-	-	3	-100.0%	-100.0%	-
Intl	229	204	12.3%	26.9%	-14.6%	421	386	9.1%	24.5%	-15.4%
WW	229	205	11.7%	26.2%	-14.5%	421	389	8.2%	23.5%	-15.3%
OTHER										
US	698	599	16.5%	16.5%	-	1,386	1,195	16.0%	16.0%	-
Intl	859	887	-3.2%	11.3%	-14.5%	1,615	1,700	-5.0%	10.4%	-15.4%
WW	1,557	1,486	4.8%	13.5%	-8.7%	3,001	2,895	3.7%	12.7%	-9.0%
TOTAL PHARMACEUTICAL										
US	3,172	3,793	-16.4%	-16.4%	-	6,846	7,863	-12.9%	-12.9%	-
Intl	2,326	2,547	-8.7%	3.3%	-12.0%	4,432	4,906	-9.7%	3.1%	-12.8%
WW	5,498	6,340	-13.3%	-8.5%	-4.8%	11,278	12,769	-11.7%	-6.8%	-4.9%

MAJOR NEW PHARMACEUTICAL PRODUCTS ⁽⁵⁾

PREZISTA										
US	65	43	51.2%	51.2%	-	137	75	82.7%	82.7%	-
Intl	75	45	66.7%	90.0%	-23.3%	125	87	43.7%	66.5%	-22.8%
WW	140	88	59.1%	71.0%	-11.9%	262	162	61.7%	73.9%	-12.2%
INVEGA										
US	67	62	8.1%	8.1%	-	133	119	11.8%	11.8%	-
Intl	32	14	128.6%	163.7%	-35.1%	57	23	147.8%	186.4%	-38.6%
WW	99	76	30.3%	36.6%	-6.3%	190	142	33.8%	39.9%	-6.1%

* See footnotes on page 3



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SECOND QUARTER					SIX MONTHS				
	2009	2008	% Change			2009	2008	% Change		
			Reported	Operational (1)	Currency			Reported	Operational (1)	Currency
MEDICAL DEVICES AND DIAGNOSTICS ^{(2) (3)}										
<u>CORDIS</u> ⁽⁶⁾										
US	252	328	-23.2%	-23.2%	-	498	670	-25.7%	-25.7%	-
Intl	422	485	-13.0%	-5.5%	-7.5%	844	944	-10.6%	-3.6%	-7.0%
WW	674	813	-17.1%	-12.6%	-4.5%	1,342	1,614	-16.9%	-12.8%	-4.1%
<u>DEPUY</u>										
US	762	722	5.5%	5.5%	-	1,528	1,431	6.8%	6.8%	-
Intl	561	606	-7.4%	6.5%	-13.9%	1,087	1,184	-8.2%	6.5%	-14.7%
WW	1,323	1,328	-0.4%	6.0%	-6.4%	2,615	2,615	-	6.6%	-6.6%
<u>DIABETES CARE</u>										
US	306	338	-9.5%	-9.5%	-	576	641	-10.1%	-10.1%	-
Intl	304	336	-9.5%	2.2%	-11.7%	575	648	-11.3%	0.5%	-11.8%
WW	610	674	-9.5%	-3.7%	-5.8%	1,151	1,289	-10.7%	-4.8%	-5.9%
<u>ETHICON</u>										
US	452	374	20.9%	20.9%	-	857	715	19.9%	19.9%	-
Intl	589	646	-8.8%	3.2%	-12.0%	1,137	1,250	-9.0%	3.5%	-12.5%
WW	1,041	1,020	2.1%	9.7%	-7.6%	1,994	1,965	1.5%	9.4%	-7.9%
<u>ETHICON ENDO-SURGERY</u>										
US	489	484	1.0%	1.0%	-	943	913	3.3%	3.3%	-
Intl	626	640	-2.2%	10.7%	-12.9%	1,187	1,214	-2.2%	11.1%	-13.3%
WW	1,115	1,124	-0.8%	6.3%	-7.1%	2,130	2,127	0.1%	7.3%	-7.2%
<u>ORTHO-CLINICAL DIAGNOSTICS</u>										
US	284	250	13.6%	13.6%	-	561	488	15.0%	15.0%	-
Intl	210	226	-7.1%	4.2%	-11.3%	400	431	-7.2%	3.8%	-11.0%
WW	494	476	3.8%	9.2%	-5.4%	961	919	4.6%	9.7%	-5.1%
<u>VISION CARE</u>										
US	231	227	1.8%	1.8%	-	465	453	2.6%	2.6%	-
Intl	399	412	-3.2%	2.0%	-5.2%	764	793	-3.7%	0.5%	-4.2%
WW	630	639	-1.4%	1.9%	-3.3%	1,229	1,246	-1.4%	1.3%	-2.7%
<u>TOTAL MEDICAL DEVICES AND DIAGNOSTICS</u>										
US	2,776	2,723	1.9%	1.9%	-	5,428	5,311	2.2%	2.2%	-
Intl	3,111	3,351	-7.2%	3.7%	-10.9%	5,994	6,464	-7.3%	3.6%	-10.9%
WW	5,887	6,074	-3.1%	2.9%	-6.0%	11,422	11,775	-3.0%	3.0%	-6.0%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Prior year amounts have been reclassified to conform with current presentation

(4) For external purposes, reported as U.S. sales

(5) Included in Other

(6) Includes sales of Drug-Eluting Stents for Q2 2009 of \$69, \$165 and \$234 million Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for Q2 2008 of \$167, \$227 and \$394 million Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for June YTD 2009 of \$136, \$349 and \$485 million Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for June YTD 2008 of \$336, \$458 and \$794 million Domestic, International and Worldwide respectively